Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 616 participants.

Also called NCT07776873

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 616 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07776873
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07776873. Randomized; single masking; primary purpose treatment. Start 2026-10-06 (actual); primary completion 2029-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke
Acronym
HOPE-MeVO
Condition
Acute Ischemic Stroke
Intervention (Drug)
Recombinant Human Prourokinase for Injection (rhPro-UK)
Intervention (Other)
Standard medical treatment (SMT)
Lead sponsor
The First Affiliated Hospital of Anhui Medical University (class: other)

Record details

Record id
cardio:ct-nct07776873
Content hash
9724301914fe99f32dca328902e554a194d0117d81c39f586af72c5c15244f75